The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index by Valentini, G et al.
1 
 
The European Scleroderma Trials and Research group (EUSTAR) Task Force for the 1 
Development of Revised Activity Criteria For Systemic Sclerosis: derivation and 2 
validation of a preliminarily revised EUSTAR activity index 3 
 4 
Gabriele Valentini1, Michele Iudici1, Ulrich A. Walker2, Veronika K. Jaeger2, Murray 5 
Baron3,  Patricia Carreira4, László Czirják5,Christopher P. Denton6, Oliver Distler7, 6 
Eric Hachulla8, Arianne Herrick9, Otylia Kowal-Bielecka10, Janet Pope11, Ulf Müller-7 
Ladner12, Gabriela Riemekasten13, Jerome Avouac14 ,Marc Frerix12, Suzana 8 
Jordan7,Tünde Minier5, Elise Siegert14,Voon H. Ong6, Serena Vettori1 and 9 
YannickAllanore15 10 
 11 
Affiliations 12 
1 Department of Clinical and Experimental Medicine, Rheumatology Section, Second 13 
University of Naples, Naples, Italy  14 
2 Department of Rheumatology, Basel University, Basel, Switzerland 15 
3 Division of Rheumatology, Jewish General Hospital, McGill University, Montreal, Quebec 16 
H3T 1E2, Canada 17 
4Department of Rheumatology, 12 de Octubre University Hospital, Madrid, Spain 18 
5 Department of Rheumatology and Immunology, University of Pécs, Medical Centre, 19 
Pécs, Hungary 20 
6 Centre for Rheumatology and Connective Tissue Disease, Division of Medicine, Royal 21 
Free Campus, University College London, London NW3 2QG, UK 22 
7 Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland 23 
8 Internal Medicine Department, Claude Huriez Hospital, Lille University, Lille, France 24 
9 Centre for Musculoskeletal Research and NIHR Manchester Musculoskeletal Biomedical 25 
Research Unit, The University of Manchester, Manchester Academic Health Science 26 
Centre, Manchester, UK 27 
10 Department of Rheumatology and Internal Medicine, Medical University of Bialystok, 28 
Bialystok, Poland 29 
11Department of Medicine, St. Joseph's Health Care, University of Western Ontario, 30 
London, Ontario N6A 4V2, Canada 31 
12 Justus-Liebig University Giessen, Department of Rheumatology and Clinical 32 
Immunology, Kerckhoff-Klinik, Bad Neuheim, Germany 33 
13 Clinic for Rheumatology, University of Lübeck, Lübeck, Germany 34 
2 
 
14 Department of Rheumatology and Clinical Immunology, University Hospital Charité, 35 
Berlin, Germany 36 
15 Cochin Institute, Paris Descartes University, INSERM U1016 and CNRS UMR8104, 37 
Paris, France 38 
 39 
IRB approval was obtained previously as EULAR/EUSTAR data were used that were 40 
collected previously on patients who had signed informed consent. 41 
Abstract 250 words, Body 3597 words, 4 Tables, 1 Figure 42 
 43 
Address Correspondence to Prof. Gabriele Valentini, Department of Clinical and 44 
Experimental Medicine, Rheumatology Section, Second University of Naples, Naples, 45 
Italy. II Policlinico, Edificio 3, Via Pansini 5, 80131 Napoli. Italia.                                                                              46 
Tel  +390815464487- Fax +390815666747- E mail gabriele.valentini@unina2.it 47 
 48 
Keywords: Systemic Sclerosis, Disease activity, Autoimmune disease 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
 65 
 66 
 67 
 68 
 69 
3 
 
Abstract 70 
Background European Scleroderma Study Group (EScSG) activity indexis currently used to 71 
assess disease activity in Systemic Sclerosis (SSc). Its validity has been criticized.  72 
Methods Three investigators  assigned an activity score on a 0-10  scale for 97 clinical charts. The 73 
median score served as gold standard. Two other investigators labelled the disease as 74 
inactive/moderately active or active/very active. Univariate-multivariate linear regression analyses 75 
were used to define variables predicting the “gold standard”, their weight and derive an activity 76 
index. The cut-off point  of the index best separating active-very active from inactive-moderately 77 
active disease was identified by a Receiver Operating Curve analysis. The index was validated on 78 
a second set of 60 charts assessed by three different  investigators on a 0-10 scale and defined as 79 
inactive/moderately active or active/very active by other 2 investigators. One hundred and twenty-80 
three were investigated for changes over time  in the index and their relationships with those in the 81 
summed Medsger severity score. 82 
Results A weighted 10-point activity index was identified and validated: Δ-skin=1.5 (Δ =patient 83 
assessed worsening during the previous month), modified Rodnan skin score>18=1.5; digital 84 
ulcers=1.5; tendon friction rubs=2.25; C reactive protein>1mg/dl=2.25; diffusing capacity of the 85 
lung for CO <70%=1.0. A cut-off ≥2.5 was found to identify patients with active disease .Changes 86 
of the index paralleled those of Medsger’s summed  severity score (p= 0.0001). 87 
Conclusions A preliminarily revised SSc activity index has been developed and validated, 88 
providing a valuable tool for clinical practice and observational studies. 89 
 90 
 91 
 92 
 93 
 94 
 95 
 96 
 97 
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Introduction 98 
 99 
The assessment of patients with systemic sclerosis (SSc) should address different disease 100 
aspects: diagnosis and fulfilment of classification criteria, extent of organ involvement, activity (the 101 
reversible part of the disease process), damage (the irreversible part of the disease process), 102 
prognosis prediction, outcome, and response to treatment.[1] Defining disease activity in SSc 103 
cannot be done using a single variable and it is challenging for a number of reasons: first, patients 104 
can  present with an indolent course, irrespective of whether or not they belong to either of the two 105 
disease subsets, i.e., diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc);[2-6] 106 
second, SSc flares can be difficult to separate from quiescent disease;[1]third, the two main 107 
morphological manifestations of the disease (interstitial fibrosis and vascular occlusion) may reflect 108 
both activity and damage and finally, validated biological markers reflecting disease activity are still 109 
lacking.[7]  110 
In 2001, the European Scleroderma Study Group (EScSG) in an analysis of the clinical charts 111 
of 290 patients from 19 European SSc centres, identified 11 disease activity variables and 112 
developed a preliminary activity index.[8,9] The construct validity of the index was first verified by 113 
the jackknife technique (i.e., assessing the dispersion of the correlation coefficients calculated by 114 
removing out 1 patient at a time), [10] then confirmed by calculating the correlations between the 115 
index and the rank of disease activity assigned by 4 experts to 30 charts, selected to represent 116 
different degrees of disease activity.[11] 117 
This index was subsequently endorsed by EUSTAR and has been used to assess disease 118 
activity in 149 studies.[12]Its criterion validity is supported by its correlation with the physician 119 
global assessment of activity of the Canadian Scleroderma Research group (CSRG), [13] its 120 
association with anti-topoisomerase1 titre,[14] and its role as the main predictor  of the 121 
scleroderma phenotype (presenting a higher procollagen transcription) of skin fibroblasts from SSc 122 
patients.[15] 123 
However, it has some limitations due to the procedure underlying its development. In fact, it 124 
most patients had a long disease duration and the number of  missing values was high. Moreover, 125 
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the face validity of hypocomplemaentemia has been questioned since the complement fixation is 126 
not thought to be important in SSc. [16,17]. Finally, it was not validated on an independent cohort. 127 
Here, we present the results of a EUSTAR study devoted to revise the original activity index in 128 
order to improve and validate it. 129 
 130 
Material and Methods 131 
Derivation study 132 
The Study Coordinator selected 97 clinical charts from patients included in the EUSTAR 133 
database.[5]The selection was carried out in order to identify patients fulfilling the 1980 ACR 134 
criteria for the classification of SSc;[18] followed in  SSc referral centres in order to reduce the 135 
number of missing values; and representing one of the following disease subgroups:  early dcSSc, 136 
late dcSSc, early lcSSc, and late lcSSc. Early disease was defined a disease duration ≤ 3 years 137 
from the onset of the first non-Raynaud symptom.[19] 138 
Three clinical investigators (YA, CD and OK-B) from centres other than those from which the 139 
patients charts were derived,  assigned a disease activity score on a 0-10  scale to each chart. The 140 
reliability of this scoring system was assessed by the evaluation of the Interclass Correlation 141 
Coefficient (ICC). The median disease activity score was used as the “gold standard” to identify 142 
items significantly  associated to disease activity.  143 
To this aim, the study coordinator selected from the items listed in the EUSTAR chart,[5]the 144 
following 18 thought to have face validity as activity variables 1)anamnestic:Δ-skin, Δ- vascular, Δ-145 
heart/lung worsening (i.e. worsening, as  evaluated by the patient during the month before 146 
enrolment, of skin induration, Raynaud’s phenomenon and/or digital ischemic ulcers and dyspnea 147 
and/or palpitations, respectively); 2) clinical: active digital ulcers; modified Rodnan skin 148 
score(mRss); tendon friction rubs(TFR); muscle weakness; arthritis;  3) laboratory: C-Reactive  149 
Protein (CRP) elevation; erythrocyte sedimentation rate (ESR)/h value; hypocomplementemia; 150 
creatin-kinase(CK) elevation; proteinuria;  4) functional and imaging : systolic Pulmonary Arterial 151 
Pressure(sPAP) and pericardial effusion  at echocardiography; ground glass and lung fibrosis at 152 
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lung High Resolution Computed Tomography (HRCT); Forced Vital Capacity(FVC); Diffusing Lung 153 
capacity for carbon monoxide-single breath (DLCO).  154 
Subsequently, we performed an univariate linear regression analysis to search for significant 155 
associations between each of the selected items and the median disease activity score given by 156 
the 3 experts. Cut-off values for sPAP, FVC  and DLCO were derived from literature.[20-22] 157 
The items significantly associated with gold standard in univariate analysis, were all entered in a 158 
multivariate linear regression analysis to identify the set of variables independently associated with 159 
the “gold standard”. As far as the remaining 2 continuous variables (mRss and ESR) , we made a 160 
number of attempts devoted to both identify the cut off point  most significantly associated with the 161 
gold standard (highest R2; lowest p)to construct a model with the highest sum of sensitivity and 162 
specificity .Each variable found to be significantly associated in multivariate analysis was assigned 163 
a weight corresponding to beta coefficient adjusted in order to construct a 10-point weighted 164 
activity index.  165 
Two other investigators (LC and GV), who were unaware of the values assigned on the 0-10 scale, 166 
evaluated each of the 97 charts as inactive (corresponding to no need to change treatment  and 167 
requiring a follow-up  after six months- 1 year), or moderately active (corresponding to no need to 168 
change treatment and a three-six-monthly follow-up), or active (needing treatment intensification 169 
and one-three-monthly follow-up), or very active (requiring hospitalization for active disease).The 170 
reliability of this system was assessed by the evaluation of Cohen’s K. The charts that had 171 
received a discordant evaluation by the 2 investigators were resent to them for a reassessment 172 
devoted to find an agreement.  173 
For each patient the overall disease activity was calculated summing the scores of the new index. 174 
The cut-off value presenting the highest sum of sensitivity and specificity in separating patients 175 
with active-very active disease from those with inactive-moderately active condition was identified 176 
by a receiver operating (ROC) curve.  177 
 178 
Validation study 179 
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The new index was validated on 60 patients recruited from the same database and selected in 180 
order to satisfy the following aspects: 1) fulfilling 2013 ACR/EULAR criteria for the classification of 181 
SSc;[23]2) belonging to patients recruited at SSc centres with SSc expertise in whom 182 
capillaroscopy  had been performed and the pattern defined according to Cutolo et al.;[24] 3) being 183 
representative of one of the following disease subgroups, as described above:  early dcSSc, late 184 
dcSSc, early lcSSc, and late lcSSc. The 60 charts were assessed for disease activity on a 0-10  185 
scale by three different investigators (PC,AH, JP) and defined as inactive, moderately active, 186 
active, and very active by other two investigators (MB and EH), all of whom unaware of the derived 187 
index. The reliability of the two scoring systems was assessed by ICC and Κ statistics respectively. 188 
Changes of the index over time and its relationships to summed Medsger severity score 189 
In order to furtherly validate the index, we assessed the changes in the activity index detected in 190 
patients from either derivation or validation cohorts in a follow-up visit at least 6 months apart and 191 
compared it with the changes in  the summed Medsger severity score[25],  that is  a validated 192 
measure  of disease severity in observational studies.[26] We undertook this approach by 193 
considering that severity reflects both activity and damage and its change, being damage 194 
irreversible, can only depend on changes in the activity part of the disease process.  195 
 196 
Results 197 
 198 
Derivation study 199 
 200 
Table 1 lists the main epidemiological, serological and clinical features of the 97 patients 201 
considered in the derivation part of this study. All of the patients also satisfied 2013 ACR/ EULAR 202 
criteria. The ICC among the activity scores given by the three clinical experts was 0.786 indicating 203 
that either the median or the mean value could be considered  consistent measures of disease 204 
activity and supporting the use of one of them as a gold standard.  205 
 206 
8 
 
TABLE 1                                                                                                                                            207 
Epidemiological, serological, capillaroscopic and clinical features of the 97 SSc patients  208 
Patients Whole 
cohort 
N=97 
Early 
dcSSc 
N=25 
Late  
dcSSc  
N=24 
Early 
lcSSc 
N=23 
Late 
lcSSc 
N=25 
Sex (F/M) 77/20 15/10 21/3 18/5 23/2 
Age (years), median; range 55 (21-89) 54 (21-70) 55 (25-75) 52 (23-89) 58 (41-75) 
Disease duration ( from the first non-
Raynaud’s manifestation):years 
(median; range) 
 
3 (0.5-47) 
 
1 (0.5-3) 
 
6 (3.1-18) 
 
2 (0.5-3) 
 
9 (4-47) 
Antinuclear antibodies positive° 95 (98) 24 24 23 24 
Anti-Scl-70 antibody positive°° 50 (51%) 15 14 11 10 
Anti-centromere antibody positive°  17 (17%) 0 2 5 10 
Anti-RNA polymerase III antibody 
positive°° 
6 (6%) 2 3 0 1 
Anti-U1RNP antibody positive°°  1 (1%) 0 0 1 0 
Raynaud’s phenomenon 97 (100%) 25 24 23 25 
Active Digital Ulcers* 16 (16%) 4 7 2 3 
Arthritis** 15 (15%) 5 4 0 6 
Proximal muscle weakness*** 29 (30%) 9 6 6 8 
Tendon Friction Rubs(TFR)**** 14 (14%) 6 3 4 1 
Skin sclerosis****** 92 (95%) 25 24 20 23 
Esophageal, stomach and/or 
intestinal involvement^ 
66 (68%) 16 
 
15 15 20 
Interstitial lung disease (CT)^^ 53/89 (59%) 13/25 17/24 10/18 13/22 
FVC^^^, % of the predicted value 
(mean±SD) 
87.5±18.9 89.4±17.3 78.7±20.0 90.8±12.8 91.0±22.3 
DLCO^^^^, % of the predicted 
value(mean±SD) 
65.7±21.5 65.9±20.1 56.5±19.9 69.9±16.4 70.6±26.3 
Estimated systolic pulmonary artery 
pressure (sPAP)>30 mmHg^^^^^ 
22 (23%) 4 5 6 7 
Heart disease^^^^^^ 45 (46%) 9 14 7 15 
Scleroderma renal crisis (previous)° 3 (3%) 2 1 0 0 
 209 
° By IF on Hep-2 cells; °° By ELISA on ANA positive sera; * ranging from small infarcts of the 210 
digital tips to digital gangrene; ** symmetric swelling and tenderness of the peripheral joints; *** as 211 
detected at physical examination; **** perception of leathery crepitus during motion of hands, 212 
wrists,elbows,shoulders, knees, ankles (both at anterior and posterior aspects) ***** thickening and 213 
induration of the skin as detected by physical examination; ^dysphagia and/or heartburn and/or 214 
bloating and/or vomiting and/or diarrhea and/or constipation; ^^either ground glass or interstitial 215 
fibrosis as detected at lung high resolution computed tomography;^^^ Forced vital capacity 216 
^^^^diffusing lung for Carbon monoxide (single breath), ^^^^^as assessed by B-MODE Doppler 217 
echocardiography; ^^^^^^ diastolic dysfunction and/or cardiac blocks and/or palpitations and/or left 218 
ventricular Ejection Fraction< 55% as assessed by EKG and B-MODE Doppler echocardiography, 219 
°rapidly deteriorating kidney failure with or without accelerated/malignant hypertension.. 220 
--------------------------------------------------------------------------------------------------------------------------------- 221 
Table 2 lists the items, out of the 19 selected, that  resulted to be associated to the median value of 222 
the three 0-10 scores,in  univariate linear regression analysis.                                                           223 
TABLE 2                                                                                                                                             224 
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Associations between each potential activity parameter and the gold standard 225 
in Univariate Regression Analysis 226 
Item R2* P 
ESR 0.441 0.0001 
Digital ulcers 0.294 0.0001 
CRP> 1 mg/dl 0.256 0.0001 
mRss 0.238 0.0001 
Δ-skin worsened 0.180 0.0001 
Δ- vascular  worsened 0.164 0.0001 
Δ-heart/lung worsened 0.160 0.0001 
CK elevation 0.127 0.0003 
TFR 0.126 0.0004 
FVC<80 % of predicted 0.114 0.0007 
Muscle weakness 0.094 0.002 
DLCO<70% of predicted  0.085 0.003 
Dyspnea and/or palpitations  0.057 0.017 
sPAP>30 mmHg 0.052 0.023 
Arthritis 0.029 0.094 
Lung fibrosis at lung HRCT 0.017 0.223 
Hypocomplementemia 0.005 0.478 
Ground glass at lung HRCT 0.0005 0.835 
   
*R-squared coefficient ;ESR. erythrocyte sedimentation rate;CRP. C-reactive protein;  mRss. 227 
modified Rodnan skin score; CK. creatin kinase; TFR. tendon friction rubs; FVC. forced vital 228 
capacity; DLCO. diffusing lung for Carbon monoxide (single breath), HRCT. high resolution 229 
computed tomography;  230 
--------------------------------------------------------------------------------------------------------------------------------- 231 
It is notable that no finding detected at high resolution computed tomography of the lung was 232 
associated to the gold standard. However, the extent of lung involvement is not defined in the 233 
EUSTAR chart.  234 
With single exceptions (e.g. tendon friction rubs for lcSSc), the same items were also associated 235 
with the gold standard in each of the 2 subsets as well as in early and late disease (data not 236 
shown).After a number of attempts, we identified a mRss> 18 and a ESR > 50 mm/h as the cut off 237 
points most significantly associated with the gold standard (highest R2; lowest p), i.e. the value 238 
corresponding to the highest association of the variable in univariate analysis. These values were 239 
entered in multivariate analysis along with the other items resulted to be associated with the gold 240 
standard. 241 
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Table 3 lists the items resulted to be associated to the gold standard in multiple regression analysis 242 
and the respective weight that was assigned depending on the β values of the regression model, in 243 
order to construct a 10-point index.  244 
Table 3 245 
Items found to be associated with the activity gold standard in multiple linear regression 246 
analysis and the resulting 2016 preliminary activity index 247 
Items beta regression 
coefficient (SE) 
p Weight 
 
Δ-skin 1.00 (0.313) 0.001 1.5 
Digital ulcers 1.078 (0.373) 0.004 1.5 
Modified Rodnan skin score > 18 1.040 (0.319) 0.001 1.5 
Tendon friction rubs 1.408 (0.317) 0.0001 2.25 
C-reactive protein > 1 mg/dl 1.401 (0.285) 0.0001 2.25 
DLCO < 70% of the predicted value 0.527 (0.259) 0.044 1.0 
 248 
SE. standard error; DLCO. Diffusing lung capacity for carbon monoxyde 249 
 250 
Since amRss lower than 18 can also reflect active disease, in the final index we considered a 251 
formulain which the highest possible value that was associated with the cut off point found to be 252 
most significantly associated with the gold standard. In detail, each mRss score lower than 18  can 253 
contribute to the overall activity score according to the following formula: mRss score x 0.084. 254 
TABLE 4 255 
REVISED EUSTAR INDEX 256 
ITEM WEIGHT  
Δ-skin 1.5 
Digital ulcers 1.5 
Modified Rodnan skin score > 18 
or for 
Modified Rodnan skin score up to 18 
1.5 
 
Scorex 0.084 
Tendon friction rubs 2.25 
C-reactive protein > 1 mg/dl 2.25 
DLCO < 70% of the predicted value 1.0 
 257 
The assessment of disease activity on the Likert scale was the same (i.e. either 258 
inactive/moderately active or active/very active) in 91 patients; differed in 6  (Cohen’s K=0.851). In 259 
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these 6 patients an agreement was reached after a re-evaluation of each chart that had given a  260 
discrepant evaluation. Out of the 97 SSc patients, 57 were considered to be inactive to moderately 261 
active; 40 active to very active.  262 
Figure 1 shows the ROC curve exploring the best cut off value discriminating between 263 
inactive-moderately active disease (no treatment change needed) and active-very active disease. 264 
A value≥2.5 resulted to have the maximal sum of sensitivity ( 80.0% ;95%CI 64.4-90.9) and  265 
specificity (91.2%;95%CI 80.7-97.1) and was used to validate the index in the validation cohort   266 
Validation 267 
Table 5 shows the epidemiological, serological, capillaroscopic and clinical features of the 268 
additional set of 60 patients selected for the validation cohort. Out of the 60 patients,47 also 269 
satisfied 1980 ACR criteria for the classification of the disease. 270 
The scores given by the three raters were significantly correlated (ICC=0.749). Moreover, their 271 
median values were significantly correlated to the respective calculated indices (Rho=0.772, 272 
95%CI 0.644-0.857; p<0.0001).The early capillaroscopic pattern was associated with the gold 273 
standard (R2=0.07; p=0.029). Nevertheless, adding it to the other items (Δ-skin; digital ulcers; 274 
modified Rodnan skin score >18; tendon friction rubs; C-reactive protein >1 mg/dl; DLCO < 70% of 275 
the predicted value) in multivariate regression analysis, did not improve the performance of the 276 
index 277 
The evaluations on the Likert scale were consistent (i.e. either inactive/moderately active or 278 
active/very active) in 46 patients; differed in 14 (Cohen’s K=0.525). In these 14 patients an 279 
agreement was reached. Out of the 60 patients, 37 were considered to be inactive to moderately 280 
active, 23 active to very active. An index ≥2.5 identified active/very active disease as defined by 281 
MB and EH with a 73.9% (95%CI 51.6-89.8) sensitivity and 78.3% (95%CI 61.8-90.2) 282 
specificity.Performing the validation process in the 47 patients also satisfying 1980 classification 283 
criteria, gave very similar results. In this cohort, a EScSG activity index ≥3 identified active disease 284 
with a 52.2% sensitivity and 89.1% specificity. 285 
 286 
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TABLE  5                                                                                                                                           287 
Epidemiological, serological, capillaroscopic and clinical features of the 60SSc patients 288 
analyzed in the validation cohort 289 
Patients Whole 
series 
n=60 
Early 
 dcSSc 
n=16 
Late  
dcSSc 
n=14 
Early 
lcSSc 
n=16 
Late  
lcSSc 
n=14 
Sex (F/M) 50/10 12/4 13/1 15/1 10/4 
Age (years), median; range 56 (24-81) 51.5 (24-75) 59.5 (33-68) 56 (25-80) 58 (44-81) 
Disease duration from 1st non-Raynaud 
manifestation (years), median; range 
2 (0-35) 1.5 (0-3) 13.5 (4-35) 1 (0-2) 8.5 (4-35) 
Antinuclear antibodies positive 58 (97%) 15 13 16 14 
Anti-Scl-70 antibody positive 24 (40%) 8 8 5 3 
Anti-centromere antibody positive  15 (25%) 0 2 6 7 
Anti-RNA polymerase I-III antibody 
positive 
9/56 (16%) 3/13 3/13 2 1 
Anti-U1RNP antibody positive  1/55 (2%) 0/13 0/12 0/16 1 
Scleroderma pattern  on nailfold 
capillaroscopy 
Early 
Active 
Late 
 
 
13 
23 
19 
 
 
1 
9 
3 
 
 
1 
3 
8 
 
 
6 
5 
5 
 
 
5 
6 
3 
Raynauds’ phenomenon 59 (98%) 16 14 15 14 
Active Digital Ulcers 14 (23%) 4 5 3 2 
Arthritis 13 (21%) 3 2 4 4 
Proximal muscle weakness 6 (10%) 1 3 1 1 
Tendon Friction Rubs (TFR) 4 (7%) 2 1 1 0 
Skin fibrosis 51 (85%) 16 13 11 11 
Esophageal, stomach and/or intestinal 
involvement 
40 (67%) 12 11 11 6 
Interstitial lung disease ( CT) 38/55 (69%) 10/14 9/12 6 6/13 
Estimated sPAP>30 mmHg 9/52 (17%) 3/12 1/13 4/13 1 
Heart disease 26 (43%) 4 7 8 7 
Scleroderma renal crisis (previous) 1 (2%) 0 0 0 1 
 290 
CT. computed tomography. sPAP. systolic pulmonary arterial pressure 291 
 292 
Changes of the index over time and its relationships to summed Medsger severity score 293 
A follow-up visit made after 6-38 months (median 13) was available in 123 out of the 157 patients 294 
from either derivation and validation cohorts. The calculated index unchanged in 36 patients, 295 
decreased in 59, increased in 28.The changes in the activity index resulted to be significantly 296 
correlated to those in the Medsger severity score in the 123 patients with a follow-up visit (Rho= 297 
0.330; 95%CI 0.162-0.479, p=0.0002), pointing out a significant relationship between the index and  298 
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the course of disease severity. In particular, at baseline, 43 out of the 123 patients had an activity 299 
index ≥ 2.5. Twenty-two resulted to have an activity index < 2.5 at the end of follow-up; out of 300 
them, 18 experienced a decrease (≥1 point), 4 a stable severity score. On the other hand, among 301 
the remaining 80 patients with a baseline activity index < 2.5, 8 resulted to develop an activity 302 
index ≥ 2.5 at the end of follow-up;out of them, 5 experienced an increase (≥1 point), 3 a stable 303 
severity score. 304 
 305 
Discussion 306 
Using the multinational EUSTAR database, we have identified a preliminarily revised set of 307 
weighted items correlated to disease activity in patients with SSc.The 2001 EScSG study [8, 9] 308 
was based on the analysis of 290 patients, most of whom with longstanding disease and was 309 
affected by a high number of missing values ensuing in a  low number of patients evaluable for 310 
most items. In order to overcome these limitations, we only relied on charts from centres with a 311 
large and scientifically supported expertise and included a high proportion of patients with early 312 
disease.  313 
The 97 patients selected for the derivation cohort present some aspects that deserve to be 314 
discussed. First, 21 out the 48 patients with lcSSc were anti-Scl-70 positive. Differences in the 315 
prevalence of anti-Scl-70 positivity among patients from different geographical regions  have long 316 
been known: 29% of French patients with lcSSc  vs 15% of American patients. [27]. Since all our 317 
patients came from European centres, this is an expected result. Secondly, 2 dcSSc patients were 318 
anticentromere antibody positive. However, this figure does not differ from the 5% prevalence of 319 
ACA in dcSSc reported by Steen et al. [28].Thirdly, 5 lcSSc patients presented tendon friction rubs. 320 
Again, tendon friction rubs have been detected in  5% of lcSSc patients supporting  the absence of 321 
any derived generalizability issues.[29] 322 
The revised EUSTAR activity index differs from the original EScSG  index in several aspects. 323 
Hypocomplementemia and arthritis were not associated with disease activity in the present study, 324 
even in univariate analysis. The role of hypocomplementemia in assessing SSc activity has been 325 
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largely debated. [16,17] Hudson et al. [30] investigated 321 patients from the Canadian 326 
Scleroderma Research Group Registry, and found that hypocomplementemia was significantly 327 
associated with inflammatory myositis and vasculitis, and concluded that it may identify a subgroup 328 
of SSc patients who have overlap disease. These data suggest that some patients enrolled in the 329 
EScSG study [31] were affected by SSc (all of them satisfied the 1980 ACR criteria)[18] in overlap 330 
with other autoimmune systemic rheumatic diseases. This aspect might also justify the exclusion of 331 
arthritis.  332 
The revised EUSTAR index contains tendon friction rubs and increased serum CRP. Tendon 333 
friction rubs were associated with diffuse and reduced survival in 1301 SSc patients.[32] This item 334 
was predictive of worsening of skin fibrosis and scleroderma renal crisis in the EUSTAR cohort.[32] 335 
CRP levels were increased in early disease and were associated with activity, skin, lung, kidney 336 
disease and poor survival in 1043 SSc patients from the CSRG Registry.[33] 337 
Similarly to the EScSG activity index, the revised  EUSTAR  index contains mRSS, digital 338 
ulcers, and DLCO. mRSS reflects the degree of skin sclerosis and has long been considered a 339 
measure of disease activity in SSc. [34] One could argue that a decreasing mRss (e.g. from 24 to 340 
18) might represent a reduced disease activity. Nevertheless, the persistence of defined skin 341 
sclerosis is not consistent with inactive disease. Digital ulcers are clearly related to vascular 342 
disease activity and have been recently found to predict the occurrence of new digital ulcers during 343 
follow-up and to be associated with cardiovascular morbidity and decreased survival.[35] A 344 
decreased DLCO can depend on both vascular and interstitial lung disease. In the absence of 345 
pulmonary hypertension, however, it has been found to provide the best overall estimate of HRCT-346 
measured lung fibrosis. [36] 347 
Similarly to the EScSG activity index, the revised EUSTAR index contains -factors (namely Δ-348 
skin). Δ-items had been criticized because they can fail to capture persistent activity and are 349 
influenced by depression.[16] Recently, however, patient assessment has been reported to be 350 
significantly correlated to mRSS, the Short Form 36 health survey physical component and skin 351 
involvement in the last month. [37] In any case, the present index is less influenced by Δ items, 352 
which represented 45% of the 2001 index with respect to the 15% of the present one.                        353 
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In the present study, three patients of the derivation cohort and 1 of the validation cohort had 354 
previously presented with scleroderma renal crisis, preventing the use of the revised EUSTAR 355 
activity index  in that context. 356 
Following the publication of the EScSG activity criteria, several attempts have been made to 357 
identify a set of criteria with an improved performance. Diaconu et al. [38] asked 6 SSc experts to 358 
evaluate 40 charts completed by clinical investigators from Nijmegen; 20 patients had early 359 
disease, not yet satisfying 1980 ACR classification criteria [18] and 20 had established disease. 360 
They derived an eight-unweighted item index (scleroderma, mRSS, fatigue, exertional dyspnoea, 361 
DLCO, musculoskeletal symptoms, ESR and digital ulcers), performing similarly to the EScSG 362 
activity index [9] in patients with either early or late disease. Furthermore, Minier et al. [39] 363 
identified two activity indexes (a 12-point extended index including  variables and a simplified 8.5-364 
point devoid of them) by investigating 131 consecutive patients at enrolment and 1 year later. 365 
These patients were assessed using a standardised protocol including high-resolution computed 366 
tomography of the lung and echocardiography. The authors confirmed the good construct validity 367 
of the original EScSG activity index and found a very good correlation both at baseline and after 1 368 
year between both the extended and the simplified score and the original EScSG activity. 369 
The SSc activity reported herein represents a step forward with respect to the EScSG activity 370 
index.[9]. First of all, unlike the EScSG activity index, it was validated on an independent 371 
cohort..Moreover, , the lower number and value of Δ-factors as well as the exclusion of disputable 372 
items like hypocomplementemia give it a greater face validity. In addition, , the greater sensitivity 373 
detected in the validation cohort make it  valuable in better charachterising the series investigated 374 
in observational studies.Finally, the revised EUSTAR activity index was found to parallel Medsger 375 
severity score over time. 376 
Our study has some limitations.                                                                                                      377 
First, the evaluation of predefined EUSTAR charts did not allow to capture either the extent of 378 
lung involvement, which has been found to be related to disease activity [40] or any change in 379 
laboratory, physical or physiologic or radiological parameter, preventing any consideration of the 380 
changes of parameters like FVC/DLCO, -fibrosis at lung HRCT or acute phase reactants. This 381 
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aspect can have prevented the inclusion of these items. In that regard, however, one should 382 
consider the possible unavailability of some previous values and the need to assess disease 383 
activity at the first patient visit. Secondly, no relevant biomarker was investigated. This limitation 384 
could be approached in the future by a collaborative multicentre study including the assessment of 385 
parameters not included in the EUSTAR chart..Finally, the lower specificity with respect to the 386 
EScSG activity index in the validation cohort requires a careful evaluation in the clinical setting e.g. 387 
the patient  with a respiratory infection presenting high CRP and low DLCO, who would be 388 
considered active according to the index, but is suffering from an unrelated condition.. 389 
In conclusion, the revised EUSTAR activity index is feasible, presents face, construct and 390 
content validity and represents a step forward to the so far widely used EScSG activity 391 
index.Future collaborative, prospective studies are needed to further improve its performance. 392 
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Figure Legends. 540 
 541 
Figure 1. Receiver Operating Curve showing the relation between the value of the 542 
calculated 2016 EUSTAR activity index and the presence of active disease in the 543 
derivation cohort. 544 
 545 
To be deleted 546 
Figure 2. Receiver Operating Curve showing the relation between a EScSG activity 547 
index ≥3 and the presence of active disease. 548 
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